Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
What To Discuss With Your Patients and Their Caregivers
Topics of discussion to have with patients and their caregivers that are informed by the comparative effectiveness review include: the importance of treatment to limit joint and tissue damage; the role of DMARDs for reducing symptoms; the potential benefits and adverse effects of DMARDs; the importance of communicating symptoms; and preferences and values of patients and caregivers regarding treatment.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.